Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Brandon Capital is a prominent life science venture capital firm based in Australasia, with a significant global presence through partnerships in the United States and the United Kingdom. Founded to support life science companies from early-stage seed investment through to expansion capital, the firm primarily focuses on Australia and New Zealand. The firm has successfully raised over A$1 billion across six funds, with its latest, Fund VI, closing at A$439 million (approximately USD $290 million) in July 2025.
Brandon Capital operates from multiple offices located in Melbourne, Sydney, San Francisco, and London. The firm has established a diverse portfolio of over 30 active companies, with a total of 90 investments historically. Their commitment to improving patient outcomes through innovative therapies has positioned them as a leader in the life sciences sector.
Brandon Capital invests primarily in life science companies, with a strong emphasis on biotechnology and pharmaceuticals. The firm supports companies at various stages, from proof-of-concept to commercialization, with a check size range of $500,000 to $10 million. Their investment strategy encompasses sectors such as oncology, neuroscience, cardiovascular health, and digital health.
Brandon Capital collaborates with a network of over 50 medical research institutes and hospitals to source and create investment opportunities. This unique approach allows them to identify promising biomedical innovations and support their development, ultimately aiming to transform medical research breakthroughs into therapies that enhance patient outcomes.
Brandon Capital boasts a diverse portfolio of over 30 active companies, including notable firms such as:
Brandon Capital has achieved significant milestones, including 1 IPO and 7 acquisitions, with 17 companies currently in clinical trials, indicating a strong pipeline of potential future successes.
Chris Nave: Founding Partner & Managing Director, with extensive experience in venture capital and life sciences.
Stephen Thompson: Founding Partner & Managing Director, known for his leadership in life sciences investments.
Melissa McBurnie: Partner & Head of Impact, focusing on the social impact of investments.
Chris Smith: Partner, contributing significant expertise in the biotech sector.
Jonathan Tobin: Partner, with a strong background in venture capital.
Duncan Mackintosh: Senior Investment Manager, specializing in early-stage investments.
Michael Bettess: Senior Investment Manager, focusing on portfolio management.
Bob Soh: Senior Investment Manager, with a focus on strategic investments.
Katherine Jackman: Senior Investment Manager, contributing to deal sourcing and evaluation.
Alex Delbridge: Principal, involved in investment analysis and portfolio support.
Helga Mikkelsen: Investment Manager, focusing on life sciences.
Prashanth Rajan: Associate, supporting investment activities.
Elliott Dunn: Associate, involved in research and analysis.
Melissa Byrne: Associate, contributing to portfolio management.
To pitch to Brandon Capital, startups should use the preferred channel of their website at brandoncapital.vc or email info@brandoncapital.com.au. The pitch deck should include a clear business model, market analysis, and details on the team. Response times may vary, but founders are encouraged to seek warm introductions where possible.
Brandon Capital manages the Brandon BioCatalyst, which supports the development and commercialization of early-stage biomedical discoveries from Australian and New Zealand research organizations. This initiative collaborates with various stakeholders, including government and medical research institutes, to enhance the innovation pipeline in life sciences.
On October 22, 2025, Brandon Capital made its latest investment, continuing its active engagement in the life sciences sector. The firm has also published a blog post titled "Where Is the White Space in Drug Development?" on January 20, 2026, showcasing its commitment to thought leadership and industry insights.
Q?
What are Brandon Capital's investment criteria?
Brandon Capital focuses on life science companies, particularly in biotechnology and pharmaceuticals, investing at various stages from seed to expansion capital.
Q?
How can startups apply or pitch to Brandon Capital?
Startups can pitch to Brandon Capital through their website at brandoncapital.vc or by emailing info@brandoncapital.com.au.
Q?
What makes Brandon Capital different from other venture capital firms?
Brandon Capital's unique Brandon BioCatalyst initiative collaborates with over 50 medical research institutions, providing proprietary deal flow and access to critical resources for portfolio companies.
Q?
What is the geographic scope of Brandon Capital's investments?
Brandon Capital invests in companies across North America, Europe, Asia, Oceania, and specifically Australia and New Zealand.
Q?
What is the typical check size for investments?
Brandon Capital typically invests between $500,000 and $10 million in their portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.